Replimune Group (REPL)
(Delayed Data from NSDQ)
$3.23 USD
-0.24 (-6.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.24 +0.02 (0.47%) 7:00 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Replimune Group, Inc. has a market cap of $270.07M, which represents its share price of $3.46 multiplied by its outstanding shares number of 78.06M. As a small-cap company, REPL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
REPL 3.23 -0.24(-6.79%)
Will REPL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REPL
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for REPL
Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty
Replimune cut to Underweight at J.P. Morgan on further headline risk
Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls
Intel downgraded, Tesla upgraded: Wall Street's top analyst calls
JP Morgan Downgrades Replimune Group (REPL) to Underweight | REPL Stock News